Fidelis Capital Partners LLC Invests $420,000 in CareDx, Inc. $CDNA

Fidelis Capital Partners LLC bought a new stake in CareDx, Inc. (NASDAQ:CDNA) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 22,280 shares of the company’s stock, valued at approximately $420,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of CDNA. First Eagle Investment Management LLC raised its stake in CareDx by 25.4% in the third quarter. First Eagle Investment Management LLC now owns 475,146 shares of the company’s stock valued at $6,909,000 after buying an additional 96,123 shares in the last quarter. Paragon Associates & Paragon Associates II Joint Venture increased its position in shares of CareDx by 93.7% during the third quarter. Paragon Associates & Paragon Associates II Joint Venture now owns 425,000 shares of the company’s stock worth $6,180,000 after purchasing an additional 205,597 shares in the last quarter. Aberdeen Group plc acquired a new stake in shares of CareDx during the fourth quarter worth about $6,506,000. ARK Investment Management LLC increased its position in CareDx by 3.4% in the 3rd quarter. ARK Investment Management LLC now owns 2,170,625 shares of the company’s stock valued at $31,561,000 after acquiring an additional 70,468 shares during the period. Finally, Zweig DiMenna Associates LLC increased its position in CareDx by 153.8% in the 3rd quarter. Zweig DiMenna Associates LLC now owns 575,000 shares of the company’s stock valued at $8,360,000 after acquiring an additional 348,400 shares during the period.

Insiders Place Their Bets

In other news, CEO John Walter Hanna, Jr. sold 10,282 shares of the stock in a transaction dated Thursday, April 16th. The shares were sold at an average price of $21.12, for a total transaction of $217,155.84. Following the transaction, the chief executive officer owned 676,475 shares of the company’s stock, valued at approximately $14,287,152. This trade represents a 1.50% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 4.40% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

CDNA has been the topic of a number of analyst reports. Wall Street Zen raised CareDx from a “buy” rating to a “strong-buy” rating in a report on Sunday, May 3rd. BTIG Research boosted their price target on CareDx from $26.00 to $28.00 and gave the stock a “buy” rating in a research note on Wednesday, April 29th. Wells Fargo & Company boosted their price target on CareDx from $18.00 to $21.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 25th. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of CareDx in a research note on Wednesday. One analyst has rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, CareDx currently has a consensus rating of “Hold” and a consensus target price of $25.00.

CareDx Stock Up 0.5%

CDNA stock opened at $22.82 on Friday. The business has a fifty day simple moving average of $19.75 and a 200-day simple moving average of $19.15. CareDx, Inc. has a 52 week low of $10.96 and a 52 week high of $23.24. The company has a market cap of $1.18 billion, a price-to-earnings ratio of -142.63 and a beta of 2.49.

CareDx (NASDAQ:CDNA) last announced its quarterly earnings results on Tuesday, April 28th. The company reported $0.34 earnings per share for the quarter, topping analysts’ consensus estimates of $0.11 by $0.23. The firm had revenue of $117.70 million during the quarter, compared to analysts’ expectations of $102.03 million. CareDx had a negative net margin of 2.01% and a negative return on equity of 2.65%. The firm’s revenue was up 39.3% on a year-over-year basis. During the same period in the prior year, the company earned $0.09 EPS. As a group, analysts expect that CareDx, Inc. will post 0.22 earnings per share for the current fiscal year.

CareDx Profile

CareDx, Inc (NASDAQ: CDNA) is a precision diagnostics company focused on the care of transplant patients. The firm develops and commercializes non‐invasive tests designed to detect organ transplant rejection and infection risk, helping physicians make informed management decisions throughout the post‐transplant journey.

The company’s core product portfolio includes AlloMap®, a gene expression profiling test for heart transplant recipients, and AlloSure®, a donor‐derived cell‐free DNA assay used primarily in kidney transplant monitoring.